Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 10:52AM ET
2.12
Dollar change
-0.07
Percentage change
-3.19
%
Index- P/E- EPS (ttm)-0.44 Insider Own22.26% Shs Outstand6.99M Perf Week-1.39%
Market Cap14.83M Forward P/E- EPS next Y-2.68 Insider Trans0.00% Shs Float5.44M Perf Month-10.17%
Income-3.31M PEG- EPS next Q-1.05 Inst Own30.29% Short Float0.43% Perf Quarter-18.77%
Sales0.00M P/S- EPS this Y93.49% Inst Trans-6.95% Short Ratio1.43 Perf Half Y-36.90%
Book/sh-3.10 P/B- EPS next Y-793.33% ROA-6.25% Short Interest0.02M Perf Year-64.45%
Cash/sh3.81 P/C0.56 EPS next 5Y- ROE- 52W Range2.07 - 13.49 Perf YTD-65.53%
Dividend Est.- P/FCF- EPS past 5Y14.92% ROI-8.64% 52W High-84.28% Beta0.09
Dividend TTM- Quick Ratio6.23 Sales past 5Y-20.00% Gross Margin- 52W Low2.42% ATR (14)0.13
Dividend Ex-Date- Current Ratio6.23 EPS Y/Y TTM90.73% Oper. Margin- RSI (14)37.83 Volatility4.97% 5.56%
Employees9 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price5.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q387.88% Payout- Rel Volume1.77 Prev Close2.19
Sales Surprise- EPS Surprise394.06% Sales Q/Q- EarningsNov 05 BMO Avg Volume16.31K Price2.12
SMA20-4.80% SMA50-12.56% SMA200-23.24% Trades Volume9,160 Change-3.19%
Date Action Analyst Rating Change Price Target Change
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Nov-05-24 07:40AM
07:30AM
Aug-06-24 01:53PM
07:34AM
07:30AM
12:00PM Loading…
May-06-24 12:00PM
May-01-24 01:53PM
07:43AM
07:30AM
Feb-27-24 08:11AM
08:00AM
06:31AM
Feb-22-24 07:41AM
07:00AM
Nov-07-23 07:47AM
07:30AM Loading…
07:30AM
Oct-20-23 01:22PM
Aug-01-23 07:40AM
07:30AM
Jun-28-23 08:30AM
Jun-09-23 09:55AM
May-18-23 12:00PM
May-15-23 09:57PM
07:40AM
07:30AM
May-10-23 08:00AM
May-08-23 08:30AM
May-01-23 07:00AM
Mar-10-23 02:24AM
Mar-08-23 11:12PM
07:30AM Loading…
07:30AM
Mar-01-23 08:30AM
Dec-29-22 10:18AM
05:30AM
Dec-28-22 08:00AM
Nov-09-22 08:00AM
Nov-02-22 08:30AM
Oct-20-22 11:28AM
Oct-17-22 09:18AM
08:51AM
08:30AM
Sep-26-22 09:21AM
Sep-09-22 04:05PM
Aug-31-22 06:25PM
Aug-23-22 12:38PM
Aug-22-22 08:00AM
Aug-12-22 09:55AM
Aug-09-22 08:00AM
Jun-22-22 08:58AM
May-04-22 08:30AM
Apr-07-22 09:57AM
08:30AM
Mar-21-22 09:52AM
Mar-01-22 09:05AM
07:30AM
Feb-28-22 08:30AM
Dec-01-21 07:44AM
Nov-08-21 08:45AM
07:30AM
Nov-03-21 08:30AM
Nov-01-21 08:30AM
Oct-11-21 08:30AM
Oct-01-21 07:00AM
Sep-30-21 10:32AM
08:30AM
Sep-27-21 08:30AM
Sep-08-21 08:30AM
Aug-02-21 08:55AM
07:30AM
Jul-26-21 03:01PM
08:30AM
Jun-10-21 08:30AM
Jun-04-21 05:20AM
May-28-21 08:00AM
May-19-21 06:19AM
May-17-21 07:57AM
May-13-21 09:01AM
May-12-21 02:35PM
10:03AM
08:30AM
07:30AM
07:20AM
06:59AM
06:45AM
May-11-21 04:15PM
May-05-21 05:10PM
Apr-07-21 08:46AM
Apr-05-21 09:31AM
Mar-08-21 12:30PM
07:30AM
05:30AM
Mar-06-21 10:57AM
Mar-01-21 08:30AM
Feb-08-21 02:30PM
01:20PM
12:30PM
11:30AM
11:13AM
11:00AM
09:43AM
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.